306 related articles for article (PubMed ID: 26918324)
1. The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients.
Nijenhuis CM; Huitema AD; Marchetti S; Blank C; Haanen JB; van Thienen JV; Rosing H; Schellens JH; Beijnen JH
J Clin Pharmacol; 2016 Oct; 56(10):1307-12. PubMed ID: 26918324
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying vemurafenib in human plasma.
Nijenhuis CM; Rosing H; Schellens JH; Beijnen JH
J Pharm Biomed Anal; 2014 Jan; 88():630-5. PubMed ID: 24216282
[TBL] [Abstract][Full Text] [Related]
3. Quantifying vemurafenib in dried blood spots using high-performance LC-MS/MS.
Nijenhuis CM; Rosing H; Schellens JH; Beijnen JH
Bioanalysis; 2014; 6(23):3215-24. PubMed ID: 25529888
[TBL] [Abstract][Full Text] [Related]
4. Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.
Puszkiel A; White-Koning M; Dupin N; Kramkimel N; Thomas-Schoemann A; Noé G; Chapuis N; Vidal M; Goldwasser F; Chatelut E; Blanchet B
Pharmacol Res; 2016 Nov; 113(Pt A):709-718. PubMed ID: 27378568
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma.
Sakji-Dupré L; Le Rhun E; Templier C; Desmedt E; Blanchet B; Mortier L
Melanoma Res; 2015 Aug; 25(4):302-5. PubMed ID: 25933211
[TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.
Garlan F; Blanchet B; Kramkimel N; Puszkiel A; Golmard JL; Noe G; Dupin N; Laurent-Puig P; Vidal M; Taly V; Thomas-Schoemann A
Target Oncol; 2017 Jun; 12(3):365-371. PubMed ID: 28527094
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a rapid and simple LC-MS/MS method for quantification of vemurafenib in human plasma: application to a human pharmacokinetic study.
Bihan K; Sauzay C; Goldwirt L; Charbonnier-Beaupel F; Hulot JS; Funck-Brentano C; Zahr N
Ther Drug Monit; 2015 Feb; 37(1):132-6. PubMed ID: 24977381
[TBL] [Abstract][Full Text] [Related]
8. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics.
Ribas A; Zhang W; Chang I; Shirai K; Ernstoff MS; Daud A; Cowey CL; Daniels G; Seja E; O'Laco E; Glaspy JA; Chmielowski B; Hill T; Joe AK; Grippo JF
J Clin Pharmacol; 2014 Apr; 54(4):368-74. PubMed ID: 24374975
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of dried blood spot (DBS) technology versus plasma analysis for the determination of MK-1775 by HILIC-MS/MS in support of clinical studies.
Xu Y; Fang W; Zeng W; Leijen S; Woolf EJ
Anal Bioanal Chem; 2012 Dec; 404(10):3037-48. PubMed ID: 23099526
[TBL] [Abstract][Full Text] [Related]
10. Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.
Kramkimel N; Thomas-Schoemann A; Sakji L; Golmard J; Noe G; Regnier-Rosencher E; Chapuis N; Maubec E; Vidal M; Avril M; Goldwasser F; Mortier L; Dupin N; Blanchet B
Target Oncol; 2016 Feb; 11(1):59-69. PubMed ID: 26208946
[TBL] [Abstract][Full Text] [Related]
11. A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients.
Alvarez JC; Funck-Brentano E; Abe E; Etting I; Saiag P; Knapp A
J Pharm Biomed Anal; 2014 Aug; 97():29-32. PubMed ID: 24814993
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of an analytical method using UPLC-MS/MS to quantify everolimus in dried blood spots in the oncology setting.
Knapen LM; Beer Y; Brüggemann RJM; Stolk LM; Vries F; Tjan-Heijnen VCG; Erp NPV; Croes S
J Pharm Biomed Anal; 2018 Feb; 149():106-113. PubMed ID: 29112898
[TBL] [Abstract][Full Text] [Related]
13. Clinical Pharmacokinetics of Vemurafenib.
Zhang W; Heinzmann D; Grippo JF
Clin Pharmacokinet; 2017 Sep; 56(9):1033-1043. PubMed ID: 28255850
[TBL] [Abstract][Full Text] [Related]
14. Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.
Nijenhuis CM; Huitema AD; Blank C; Haanen JB; van Thienen JV; Rosing H; Schellens JH; Beijnen JH
J Clin Pharmacol; 2017 Jan; 57(1):125-128. PubMed ID: 27365214
[No Abstract] [Full Text] [Related]
15. Manual punch versus automated flow-through sample desorption for dried blood spot LC-MS/MS analysis of voriconazole.
Martial LC; van den Hombergh E; Tump C; Halmingh O; Burger DM; van Maarseveen EM; Brüggemann RJ; Aarnoutse RE
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jul; 1089():16-23. PubMed ID: 29747155
[TBL] [Abstract][Full Text] [Related]
16. Dried blood spot analysis for therapeutic drug monitoring of pazopanib.
de Wit D; den Hartigh J; Gelderblom H; Qian Y; den Hollander M; Verheul H; Guchelaar HJ; van Erp NP
J Clin Pharmacol; 2015 Dec; 55(12):1344-50. PubMed ID: 26032288
[TBL] [Abstract][Full Text] [Related]
17. Suitability of methylmalonic acid and total homocysteine analysis in dried bloodspots.
de Sain-van der Velden MGM; van der Ham M; Jans JJ; Visser G; van Hasselt PM; Prinsen HCMT; Verhoeven-Duif NM
Anal Chim Acta; 2015 Jan; 853():435-441. PubMed ID: 25467488
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of a dried blood spot method for determination of mycophenolic acid in renal transplant patients.
Arpini J; Antunes MV; Pacheco LS; Gnatta D; Rodrigues MF; Keitel E; Linden R
Clin Biochem; 2013 Dec; 46(18):1905-8. PubMed ID: 24161478
[TBL] [Abstract][Full Text] [Related]
19. Determination of the HCV Protease Inhibitor Telaprevir in Plasma and Dried Blood Spot by Liquid Chromatography-Tandem Mass Spectrometry.
Verweij-van Wissen CP; de Graaff-Teulen MJ; de Kanter CT; Aarnoutse RE; Burger DM
Ther Drug Monit; 2015 Oct; 37(5):626-33. PubMed ID: 25627404
[TBL] [Abstract][Full Text] [Related]
20. A Validated Assay to Quantify Osimertinib and Its Metabolites, AZ5104 and AZ7550, from Microsampled Dried Blood Spots and Plasma.
Venkatesh B; Yuile A; McKay MJ; Narayanan S; Wheeler H; Itchins M; Pavlakis N; Clarke SJ; Molloy MP
Ther Drug Monit; 2024 Jun; 46(3):332-343. PubMed ID: 38263583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
